Benzinga | Oct 29, 2021 09:06AM EDT

Dr. Reddy's Laboratories Announces Launch Of Ephedrine Sulfate Injection USP, 50 mg/mL, Single-Dose Vial In U.S. Market

Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's")) today announced the launch of Ephedrine Sulfate Injection USP, 50 mg/mL, a therapeutic equivalent generic version of Akovaz(r) (ephedrine sulfate injection) Injection, 50 mg/mL approved by the U.S. Food and Drug Administration (USFDA).

The Akovaz(r) brand and generic market had U.S. sales of approximately $67.5 million MAT for the most recent twelve months ending in August 2021 according to IQVIA Health*.

Dr. Reddy's Ephedrine Sulfate Injection USP, 50 mg/mL is a clear, colorless, sterile solution for intravenous injection and supplied as a 1 mL fill in a 2 mL clear glass single-dose vial with purple flip-off cap. Each mL contains 50 mg of ephedrine sulfate USP, equivalent to 38 mg ephedrine base.

Please clickhere for full prescribing information: https://www.drreddys.com/pi/Ephedrine-Sulfate-Inj-Leaflet-150085475.pdf

Akovaz(r) is a trademark of EXELA STERILE MEDICINES LLC

*IQVIA Retail and Non-Retail MAT August 2021